Unicycive Therapeutics Inc. (NASDAQ: UNCY) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT UNICYCIVE THERAPEUTICS INC.

Unicycive Therapeutics Inc. (NASDAQ: UNCY)
Listen to this Section


$7.32
+0.0850 ( +1.18% ) 322.1K

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.

Clinical Trial Pipeline Stages


Drug Name Stage
UNI-494DetailsAcute Kidney Injury, Kidney disease Phase 1

Market Data


Open $7.32
Previous Close $7.23
Volume 322.1K
Market Cap $193.04M
Day Range $7.10 - $7.54
52 Week Range $3.71 - $11.00
Shares Outstanding 26.70M
Change % +1.18%
Net Change ▲ 0.0850
Insider Ownership -0.59%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2021
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -11,537,313.00

Date Type Amount Purchased Purchaser
2024-08-14 Sale -232868.00 Gupta Shalabh K.
2024-08-14 Sale -40256.00 Townsend John
2024-08-14 Sale -81750.00 Jermasek Douglas
2024-08-14 Sale -81750.00 Gupta Pramod
2024-04-17 Sale -228119.00 Townsend John
2024-04-17 Sale -463250.00 Gupta Pramod
2024-04-17 Sale -1319583.00 Gupta Shalabh K.
2024-04-17 Sale -463250.00 Jermasek Douglas
2023-09-07 Sale -180000.00 Kenkare-Mitra Sara
2023-09-07 Sale -180000.00 Aggarwal Gaurav

SEC Filings


Form Type Description Pages Date
4 Insider transactions 1 Jul 30, 2025
4 Insider transactions 1 Jul 30, 2025
4 Insider transactions 1 Jul 30, 2025
4 Insider transactions 1 Jul 30, 2025
4 Insider transactions 1 Jul 30, 2025
8-k 8K-related 14 Jul 08, 2025
8-k 8K-related 14 Jun 30, 2025
8-k 8K-related 15 Jun 20, 2025
8-k 8K-related 14 Jun 10, 2025
8-k 8K-related 12 Jun 09, 2025

Latest News


× Before browsing our site, please accept our cookies policy